{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Other Investigations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Other Blood/lymphatics"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cardiac Disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Gastrointestinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"General disorders and administration site conditio"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Infections and infestations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Metabolism and nutrition disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Musculoskelatal and connective tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neoplasms benign, malignant and unspecified"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Peripheral sensory neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Other nervous system disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Respitory, thoracic and mediastinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Vascular disorders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0","groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Ixabepilone"}],"paramType":"NUMBER","populationDescription":"Eligible and Treated Participants","reportingStatus":"POSTED","timeFrame":"During treatment and up to 30 days after stopping the study treatment","title":"Adverse Events (Grade 3 or Higher) During Treatment Period.","type":"PRIMARY","unitOfMeasure":"participants"}